Clinical Trial Search

Primary: Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST — 1; 0; 0; 0 participants

Primary: Adherence Rate to Diagnosis Imaging Guidelines for Patients With a Deep Sarcoma Tumor (Before Implementation of the Public Health Intervention Programme. — 145…

Primary: Overall Objective Response — 5; 22; 8 participants

Primary: Objective Response (Confirmed, Complete and Partial) — 1; 0; 1; 8 participants

Primary: Best Anatomical Tumor Response — 0; 2; 22; 30 participants

Primary: Number of Participants With Engraftment — 23 Participants

Primary: Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria. — 8 events

Primary: Part 2: Radiologic Progression-free Survival (PFS) — 18.7; 24.1 weeks — p== 0.6562

Primary: Change in Fludeoxyglucose (FDG) Uptake (Maximal Standardized Uptake Value, or SUVmax)

Primary: Overall Objective Response — 1; 21; 26 participants

Primary: Number of Participants With Overall Response (OR) — 1 participants

Primary: Percentage of Participants With Progression-Free Survival (PFS) at 12 Weeks — 27.3; 12.5; 25.4; 50.0 percentage of participants

Primary: Pathologic Response Rate, Defined as the Percentage of Participants With Greater Than or Equal to 95% Necrosis. — 20 % of participants

Primary: Retention — 9 Participants

Primary: Number of Participants With Grade 3 Bilirubin — 3 participants with Grade 3 Bilirubin

Primary: Number of Patients With Dose Limiting Toxicities. — 0; 1; 0 Participants

Primary: Response Rate (Per RECIST 1.1) — 1 Participants

Primary: Antitumor Activity as Assessed by Number of Patients Showing an Objective Tumor Response — 0 participants

Primary: Progression-free Survival (PFS). Cohort A and Cohort B — 1.87; 2.07; 3.6; 1.7 months

Primary: Probability for Event Free Survival. — 0.8984; 0.7647; 0.6079; 0.4873 Probability of EFS at 5 years

Primary: Lesion-specific Local Control at 6 Months Post-SBRT as Assessed by Percentage of Lesions Locally Controlled — 95 percentage of lesions

Primary: The Primary Endpoint for This Trial Was the Percent of Confirmed Tumor Responses. Confirmed Tumor Response to Treatment Was Defined as a Complete or Partial Response(Per…

Primary: Progression-free Survival (PFS) (Arm 1 Only) — 5.48 months

Primary: Overall Response Rate (ORR) — 9; 3; 6 participants

Primary: Percentage of Patients With Progression-free Survival at 16 Weeks. — 36.4 Percentage of patients

Primary: Number of Dose Limiting Toxicities — 0; 2 DLTs

Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient

Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months

Primary: Overall Survival (OS) — 13.73; 13.14 Months

Primary: Response Rate (CR + PR) Assessed by RECIST 1.1 (Phase II) — 4; 1; 5; 0 participants